Table 5.
Utility of nSMase2 inhibition in preclinical infectious disease models
| Disease | Model | Result of nSMase2 inhibition | Refs |
|---|---|---|---|
| CMV | Primary human dermal fibroblasts | Decreased propagation of HCMV | [108] |
| DENV | C6/36 cells | Decreased EVs and viral load | [106] |
| Epsilon toxin | ACHN cells | Inhibited toxin-mediated ceramide formation and cytotoxicity | [110] |
| HCV | Huh7-Lunet-TLR3 cells | Decreased secretion of infectious virus | [103] |
| HEV | PLC/PRF/5 cells | Decreased secretion of infectious virus | [104] |
| HIV | DCs and CD4+ T cells | Blocked trans-infection from HIV-1-infected cells to healthy DCs and CD4+ T lymphocytes | [100] |
| Langat virus | ISE6 and HaCaT cells | Inhibited release of tick cell-derived EVs and decreased viral RNA transmission | [105] |
| NDV | DF-1 cells | Decreased EV release from infected cells and decreased extracellular levels of virus | [109] |
| Rabies virus | Vero cells | Decreased levels of viral RNA | [107] |
| Shiga toxin | THP-1 cells | Decreased toxin-mediated human renal cell death | [111] |
| Zika virus | Human fetal astrocytes | Decreased EV release and suppressed virus propagation | [101] |
| Primary murine cortical neurons | Reduced EV release and diminished viral RNA levels | [102] |